Clozapine

GPTKB entity

Statements (63)
Predicate Object
gptkbp:instance_of gptkb:drug
gptkbp:bfsLayer 5
gptkbp:bfsParent gptkb:Searle_Pharmaceuticals
gptkbp:activities dopamine receptor antagonist
gptkbp:approves gptkb:1990
gptkb:FDA
gptkbp:associated_with improved quality of life
reduction in hospitalizations
improved social functioning
lower risk of suicide
gptkbp:brand gptkb:Clozaril
Faza Clo
gptkbp:caused_by gptkb:hospital
gptkb:Company
metabolic syndrome
hyperlipidemia
pulmonary embolism
hyperglycemia
extrapyramidal symptoms
QT prolongation
neuroleptic malignant syndrome
myocarditis
gptkbp:clinical_trial Phase III
50% to 60%
gptkbp:contraindication history of agranulocytosis
gptkbp:developed_by gptkb:Sandoz
gptkbp:discontinued in patients with severe CNS depression
gptkbp:disease_resistance treatment-resistant schizophrenia
gptkbp:dosage_form 300 to 900 mg/day
gptkbp:healthcare gptkb:1990
https://www.w3.org/2000/01/rdf-schema#label Clozapine
gptkbp:ingredients C18 H19 Cl N4
gptkbp:interacts_with gptkb:beer
benzodiazepines
CY P2 D6 inhibitors
CY P3 A4 inhibitors
gptkbp:is_atype_of N05 A H02
gptkbp:is_available_in multiple countries
gptkbp:is_available_on gptkb:tablet
oral suspension
gptkbp:is_effective_against cognitive symptoms of schizophrenia
negative symptoms of schizophrenia
gptkbp:is_monitored_by white blood cell count
gptkbp:is_used_for treatment of schizophrenia
gptkbp:lifespan 12 hours
gptkbp:manager oral
gptkbp:metabolism CY P1 A2
gptkbp:requires patient registry for monitoring
gptkbp:research_focus genetic factors
neuroinflammation
pharmacogenomics
neurotransmitter systems
gptkbp:side_effect dizziness
seizures
constipation
weight gain
sedation
tachycardia
agranulocytosis
hypersalivation
gptkbp:suitable_for elderly patients with dementia-related psychosis
gptkbp:treatment not first-line treatment
gptkbp:uses requires regular blood tests